New Data Show NEXTSTELLIS® Has Selective Impact On Endocrine Markers Compared With Common Combined Oral Contraceptives
- Sunday, March 7, 2021, 7:00
- Finance
- Add a comment
RALEIGH, N.C., March 6, 2021 /PRNewswire/ — Mayne Pharma announced today new data showing treatment with NEXTSTELLIS®,1 a novel, investigational combined oral contraceptive (COC) containing drospirenone (DRSP) and estetrol (E4), resulted in limited changes in endocrine markers, including…
About the Author
adminasapcorp has written 41546 stories on this site.